Rajaprabhakaran Rajarethinam, MD
Psychiatry · Ann Arbor, MINPI 1427095918
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Johnson & Johnson at 42.0% of the total. Reporting peaked in 2019 at $21,634 and has fallen 88.6% since, to $2,456 in 2023. Among psychiatry clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 91 payments — averaging $318.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$12K
- Neurocrine Biosciences, Inc.$9K
- Alkermes, Inc.$5K
- Livanova USA, Inc.$1K
- Avanir Pharmaceuticals, Inc.$1K
- Otsuka Pharmaceutical Development & Commercialization, Inc.$175
- plus $41 from 1 others
Across 333 payments — averaging $3450.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Livanova USA, Inc.$298K
- E.r. Squibb & Sons, L.L.C.$147K
- Boehringer Ingelheim$123K
- Biohaven Pharmaceutical Holding Company Ltd.$112K
- Neurocrine Biosciences, Inc.$109K
- F. Hoffmann-la Roche AG$94K
- plus $267K from 9 others
What the payments were for
- Consulting fees$5,17518%
- Speaking & faculty fees$16,58057%
- Travel & lodging$4,74716%
- Food & beverage$2,4558%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 37 | $12,159 |
| Neurocrine Biosciences, Inc. | 26 | $8,798 |
| Alkermes, Inc. | 6 | $5,498 |
| Livanova USA, Inc. | 7 | $1,202 |
| Avanir Pharmaceuticals, Inc. | 10 | $1,085 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $175 |
| Neuronetics, Inc. | 4 | $41 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$21,693
- SPRAVATO$11,778
- INGREZZA$6,124
- ARISTADA INITIO$5,423
- VNS Therapy$993
- ABILIFY MYCITE$175
How this compares
$28,958 in reported general payments places this provider in the 95th percentile of 1,166 psychiatry providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 11 | $13,886 |
| Clozapine OdtClozapine | 13 | $10,870 |
| Clozapine | 65 | $4,222 |
| Quetiapine Fumarate | 27 | $4,012 |
| Asenapine Maleate | 15 | $1,931 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $941 |
| Fluphenazine Hcl | 24 | $877 |
| Ziprasidone Hcl | 16 | $700 |
| Olanzapine | 33 | $648 |
| Divalproex Sodium | 21 | $606 |
| Duloxetine Hcl | 21 | $526 |
| Aripiprazole | 44 | $479 |
| Lithium Carbonate | 29 | $446 |
| Atomoxetine Hcl | 11 | $404 |
| Haloperidol Decanoate | 13 | $362 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $12,159 | $13,88611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,166 psychiatry providers in Michigan.
Other psychiatry in Ann Arbor
- Sagar ParikhAnn Arbor$83K
- Juan LopezAnn Arbor$21K
- Sara BobakAnn Arbor$13K
- Andreas SidiropoulasDetroit$2.8M
- Welton WashingtonYpsilanti$1.4M
- Joel YoungRochester Hills$1.1M
- Manzar RajputMonroe$612K
- William GuySouthfield$562K
- Robert LagrouClarkston$267K
- Michael IngramBay City$255K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.